| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid D2 targets multiple pathways involved in cancer, inflammation, and immunity. As a triterpenoid from Ganoderma lucidum, it has anticancer, anti-inflammatory, and immunomodulatory effects. Its mechanism of action may involve modulation of inflammatory mediators, oxidative stress, and immune cell function.
|
|---|---|
| ln Vitro |
In vitro, Ganoderic acid D2 has anticancer, anti-inflammatory, and antioxidative activity. It is used to study the effects of triterpenoids on cancer cell proliferation, inflammation, and oxidative stress. Its activity is measured by assessing cell viability, apoptosis, cytokine production, and antioxidant capacity in cultured cells.
|
| ln Vivo |
In vivo, Ganoderic acid D2 possesses anticancer, anti-inflammatory, and immunomodulatory effects. It is derived from the medicinal mushroom Ganoderma lucidum. Its pharmacological activities make it a compound of interest for the study of cancer, inflammatory diseases, and immune disorders.
|
| Enzyme Assay |
In vitro enzyme assays with Ganoderic acid D2 typically involve studying its effects on enzymes involved in inflammation, oxidative stress, or cancer pathways. Standard assays may measure antioxidant activity (e.g., DPPH radical scavenging), anti-inflammatory activity (e.g., COX inhibition), or anticancer activity (e.g., caspase activation). These assays help characterize its mechanism of action.
|
| Cell Assay |
In vitro cell culture experiments with Ganoderic acid D2 involve treating various cancer cell lines or immune cells with the compound. Cells are treated with various concentrations, and endpoints include assessment of cell viability (MTT assay), apoptosis, cytokine production, and gene expression changes. These experiments characterize the anticancer and anti-inflammatory effects of the compound.
|
| Animal Protocol |
In vivo animal experiments with Ganoderic acid D2 typically involve using animal models of cancer, inflammation, or immune disorders. The compound is administered orally or intraperitoneally, and key endpoints include tumor growth inhibition, inflammatory markers, immune cell populations, and histopathological examination of tissues. These studies evaluate the therapeutic potential of ganoderic acid D2.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Ganoderic acid D2 are not extensively characterized. As a triterpenoid (molecular weight 530.65), it is expected to have moderate oral bioavailability. It is likely metabolized in the liver and excreted in bile and urine. Its solubility in water is very low (0.041 g/L at 25°C). Specific PK parameters would need to be determined in future studies.
|
| Toxicity/Toxicokinetics |
Ganoderic acid D2 has a low toxicity profile based on its natural occurrence in Ganoderma lucidum, which has a long history of medicinal use. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound.
|
| References | |
| Additional Infomation |
7,12-Dihydroxy-3,11,15,23-Tetraoxolanostane-8-en-26-acid is a triterpenoid compound. It has been reported that Ganoderma lucidum contains 7,12-dihydroxy-3,11,15,23-tetraoxolanostane-8-en-26-acid, and related data have been reported.
Ganoderic acid D2 is a triterpenoid compound derived from the medicinal mushroom Ganoderma lucidum (Reishi). It possesses various pharmacological activities, including anticancer, anti-inflammatory, immunomodulatory, and antioxidative effects. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C30H42O8
|
|---|---|
| Molecular Weight |
530.65
|
| Exact Mass |
514.293
|
| CAS # |
97653-94-6
|
| PubChem CID |
14109398
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
688.3±55.0 °C at 760 mmHg
|
| Melting Point |
201 - 203 °C
|
| Flash Point |
384.1±28.0 °C
|
| Vapour Pressure |
0.0±4.9 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.43
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1150
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(C(C(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)O)C)C
|
| InChi Key |
LCIUOVOXWPIXOR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H42O8/c1-14(10-16(31)11-15(2)26(37)38)17-12-21(34)30(7)22-18(32)13-19-27(3,4)20(33)8-9-28(19,5)23(22)24(35)25(36)29(17,30)6/h14-15,17-19,25,32,36H,8-13H2,1-7H3,(H,37,38)
|
| Chemical Name |
6-(7,12-dihydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (47.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8845 mL | 9.4224 mL | 18.8448 mL | |
| 5 mM | 0.3769 mL | 1.8845 mL | 3.7690 mL | |
| 10 mM | 0.1884 mL | 0.9422 mL | 1.8845 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
